Aura Biosciences (AURA) vs 4D Molecular Therapeutics (FDMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Aura Biosciences (AURA) over the past year, gaining 51.3% versus a gain of 12.2%. 4D Molecular Therapeutics is the larger company by market cap ($676.2 million vs $674.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | FDMT |
|---|---|---|
| Share price | $6.50 | $12.24 |
| Market cap | $674.08M | $676.19M |
| 1-day change | +0.62% | -2.78% |
| YTD return | +18.53% | +67.87% |
| 1-year return | +12.15% | +51.32% |
| 5-year return | — | -53.92% |
| EPS (TTM) | $-1.75 | $-2.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $16.93 |
| 52-week low | $4.73 | $6.96 |
| Distance from 52-week high | -31.83% | -27.70% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +155.38% | +129.49% |
| Average volume | 740.43K | 921.65K |
| Shares outstanding | 103.70M | 55.24M |
| Employees | 113 | 196 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed AURA by 39.2 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
AURA vs FDMT FAQ
Which is bigger, Aura Biosciences or 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $676.19M compared with $674.08M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or FDMT?
FDMT returned +51.32% over the past 12 months, compared with +12.15% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and 4D Molecular Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.